On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at their December 2023 meeting. Actions in this consultation include:

  • Cytisine 1.5mg tablets for smoking cessation – add as GREEN
  • Empagliflozin for chronic heart failure with preserved or mildly reduced ejection fraction – GREEN (following specialist advice)
  • Foslevodopa-foscarbidopa for advanced Parkinson’s disease with motor symptoms – RED

All links to NICE clinical guidelines and MHRA drug safety updates will be added to formulary as appropriate.

The consultation will run for six weeks and closes at 5pm on Tuesday 23rd January 2024. To take part, visit the consultations page.